Shots:

• The SoliMix study evaluates the efficacy & safety of Soliqua vs premixed insulin (BIAsp 30) in 887 adults with T2D who were uncontrolled on insulin + metformin with/ out SGLT-2 for 26 wks.
• The study met its 1EPs & 2EPs that showed noninferiority in reduction of HbA1c & superiority on body weight change from baseline- a greater proportion of patients reach on HbA1c target of <7% without weight gain & without hypoglycemia while safety findings were consistent with the established profiles of both treatments
• The secondary analysis also showed greater improvements in PRO as measured by TRIM-D & GTEE scores @ 26 wks. The findings were presented at ADA2021

  | Ref: Sanofi | Image: Medcity News